赛恩斯（688480）：2025年中报点评：业务结构改善，药剂业务快速发展

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown improvement in its business structure, with rapid development in its chemical agent business [1] - The report highlights a significant increase in revenue and a focus on expanding the chemical agent product line, which is expected to drive future growth [1] Financial Performance Summary - For 2023, total revenue is projected at 808.40 million, with a year-on-year growth of 47.47% - The net profit attributable to the parent company for 2023 is estimated at 90.33 million, reflecting a year-on-year increase of 36.39% - The earnings per share (EPS) for 2023 is expected to be 0.95 yuan, with a price-to-earnings (P/E) ratio of 44.42 [1][8] Revenue and Profit Forecast - Total revenue is forecasted to reach 1,271.09 million in 2025, representing a year-on-year growth of 37.09% - The net profit attributable to the parent company is expected to be 163.15 million in 2025, showing a decrease of 9.74% compared to 2024 [1][8] - The EPS for 2025 is projected at 1.71 yuan, with a P/E ratio of 24.59 [1][8] Business Segment Performance - The chemical agent revenue for the first half of 2025 is expected to be 1.66 billion, with a year-on-year growth of 42% - The gross margin for the chemical agent segment is projected to be 45%, contributing to 51% of the total gross profit [1] - The company has made significant investments in expanding its production capacity for copper extractants and other chemical products [1] Strategic Initiatives - The company has implemented a stock incentive plan aimed at achieving a compound annual growth rate of 17% in net profit from 2025 to 2027, reflecting confidence in future growth [1] - The report emphasizes ongoing efforts in market development and technological research, which are expected to enhance the company's competitive position [1]